Stockscreener 앱 받기
4.01
2.69%
0.105
시간 외 거래:
4.01
Newcelx Ltd 주식(NCEL)의 최신 뉴스
Enterprise value to EBIT forward of NewcelX Ltd. – BOATS:NCEL - TradingView
Enterprise value to revenue forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
NCELNewcelX Ltd Volatility & Greeks - Finviz
NewcelX Wins FDA Backing to Advance NCEL-101 Toward Type 1 Diabetes Trials - TipRanks
NewcelX receives FDA feedback on type 1 diabetes therapy plan - Investing.com
NewcelX Announces Successful FDA Pre-IND Meeting for NCEL-101 Type 1 Diabetes Program - Quiver Quantitative
NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes - marketscreener.com
NewcelX Shareholders Approve All Proposals at June 30 Annual Meeting - TipRanks
Number of shareholders of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Number of shareholders of NewcelX Ltd. – BOATS:NCEL - TradingView
NewcelX Ltd. Actuals & Estimates (NASDAQ:NCEL) - TradingView
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NCEL Should I Buy - Intellectia AI
NewcelX Ord Shs (NCEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewcelX Ord Shs (NCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewcelX Ord Shs (NCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NewcelX Ord Shs (NCEL) Institutional Confidence - TradingKey
[EFFECT] NewcelX Ltd. SEC Filing - Stock Titan
NewcelX Ord Shs (NCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewcelX Ord Shs (NCEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewcelX Ord Shs (NCEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NewcelX Ord Shs (NCEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exclusive: NewcelX eyes accelerated 2026 execution for diabetes drug - MSN
NewcelX Stem Cell Platform Strengthened by Peer-Reviewed AstroRx Study in Multiple Sclerosis - TipRanks
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform - The Manila Times
Peer-reviewed AstroRx data underscore NewcelX (NCEL) stem cell platform - Stock Titan
NewcelX Ltd. (NCEL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NewcelX Calls June 30, 2026 Shareholders’ Meeting as 2025 Losses Deepen - TipRanks
NewcelX Stock Moves Up Ahead of FDA Meeting on Diabetes Treatment - Bez Kabli
Exclusive: NewcelX advances diabetes therapy toward human trials with FDA pre-IND submission - MSN
NewcelX Ltd. (NCEL) Gains Ground: Testing Key Resistance LevelsStatistical Arbitrage - newsline.com
Newcelx submits pre-IND package for NCEL-101 to FDA - BioWorld News
NewcelX Files Pre-IND With FDA for NCEL-101 Type 1 Diabetes Cell Therapy - TipRanks
Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes - marketscreener.com
NewcelX (Nasdaq: NCEL) files FDA pre-IND for NCEL-101 diabetes cell therapy - Stock Titan
NewcelX Ltd. Schedules Pre-IND Meeting with FDA to Propel Type 1 Diabetes Treatment NCEL-101 into First-In-Human Trials - Quiver Quantitative
Stem cell therapy targeting a potential type 1 diabetes cure nears trials - Stock Titan
NCEL Stock Price, Quote & Chart | NEWCELX LTD (NASDAQ:NCEL) - ChartMill
TradingKey - TradingKey
NewcelX (NASDAQ: NCEL) registers 2.26M shares for resale by investors - Stock Titan
Why NewcelX (NCEL) is still under the radar (Risk Aversion) 2026-05-06Top Analyst Buy Signals - Newser
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares - Quantisnow
NewcelX Ltd. (NCEL) updates resale prospectus for up to 500,000 shares - Stock Titan
How NewcelX (NCEL) differentiates itself from competitors (Investor Concern) 2026-05-05High Interest Stocks - newser.com
Julien Ruggieri Discloses Investment at NewcelX Ltd. with 25.3% Stake - TradingView
League Jinn holds 25.3% ownership stake in NewcelX (NCEL) - Stock Titan
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - Yahoo Finance
NLSPW SEC FilingsNEWCELX LTD 10-K, 10-Q, 8-K Forms - Stock Titan
Olivier Samuel Buys Handful Of Shares In NewcelX - 富途牛牛
Despite NewcelX's Pullback, Insiders Still Gained ₪136k - Yahoo Finance
NewcelX Loses US$2.3m Market Value But Insiders See Windfall Of ₪136k - simplywall.st
1.17%
2.48%
자본화:
|
볼륨(24시간):